

# Role of adenosine A<sub>2B</sub> receptor signaling in contribution of cardiac mesenchymal stem-like cells to myocardial scar formation

Sergey Ryzhov · Bong Hwan Sung · Qinkun Zhang ·  
Alissa Weaver · Richard J. Gumina · Italo Biaggioni ·  
Igor Feoktistov

Received: 19 September 2013 / Accepted: 18 February 2014 / Published online: 1 March 2014  
© Springer Science+Business Media Dordrecht 2014

**Abstract** Adenosine levels increase in ischemic hearts and contribute to the modulation of that pathological environment. We previously showed that A<sub>2B</sub> adenosine receptors on mouse cardiac Sca1<sup>+</sup>CD31<sup>-</sup> mesenchymal stromal cells upregulate secretion of paracrine factors that may contribute to the improvement in cardiac recovery seen when these cells are transplanted in infarcted hearts. In this study, we tested the hypothesis that A<sub>2B</sub> receptor signaling regulates the transition of Sca1<sup>+</sup>CD31<sup>-</sup> cells, which occurs after myocardial injury, into a myofibroblast phenotype that promotes myocardial repair and remodeling. In vitro, TGFβ1 induced the expression of the myofibroblast marker α-smooth muscle actin (αSMA) and increased collagen I generation in Sca1<sup>+</sup>CD31<sup>-</sup> cells. Stimulation of A<sub>2B</sub> receptors attenuated TGFβ1-induced collagen I secretion but had no effect on αSMA expression. In vivo, myocardial infarction resulted in a rapid increase in the numbers of αSMA-positive cardiac stromal cells by day 5 followed by a gradual decline. Genetic deletion of A<sub>2B</sub> receptors had no effect on the initial accumulation of αSMA-expressing stromal cells but hastened their subsequent decline; the numbers of αSMA-positive cells including Sca1<sup>+</sup>CD31<sup>-</sup> cells remained significantly higher in wild type

compared with A<sub>2B</sub> knockout hearts. Thus, our study revealed a significant contribution of cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells to the accumulation of αSMA-expressing cells after infarction and implicated A<sub>2B</sub> receptor signaling in regulation of myocardial repair and remodeling by delaying deactivation of these cells. It is plausible that this phenomenon may contribute to the beneficial effects of transplantation of these cells to the injured heart.

**Keywords** Adenosine · Receptor · Adenosine A<sub>2B</sub> · Mesenchymal stromal cells · Myofibroblasts · Myocardial infarction · Alpha-smooth muscle actin

## Introduction

Cardiac multipotent mesenchymal stem-like cells have been proposed as candidates for cell-based transplantation therapy to enhance tissue repair and functional recovery after myocardial infarction (MI) [1, 2]. In the mouse's heart, these cells are represented by a population of stromal cells characterized by cell-surface expression of stem cell antigen (Sca)-1 and absence of the endothelial cell marker CD31 [3–11]. Several groups, including our laboratory, have demonstrated that the delivery of cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells to the injured heart attenuates the decline in cardiac function and the adverse remodeling in animal models of MI [6, 9, 11–13].

MI is known to increase interstitial adenosine concentrations to levels sufficient to engage all adenosine receptors, including the low-affinity A<sub>2B</sub> subtype [14–16]. The A<sub>2B</sub> receptor is expressed on mesenchymal stem/progenitor cells isolated from various tissues [10, 17–22] and represents the functionally predominant adenosine receptor subtype in cardiac Sca1<sup>+</sup> mesenchymal stem-like cells [10]. Importantly, we have recently demonstrated that A<sub>2B</sub> adenosine receptor

**Electronic supplementary material** The online version of this article (doi:10.1007/s11302-014-9410-y) contains supplementary material, which is available to authorized users.

S. Ryzhov · B. H. Sung · Q. Zhang · A. Weaver · R. J. Gumina ·  
I. Biaggioni  
Divisions of Cardiovascular Medicine (SR, QZ, RJG, IF) and  
Clinical Pharmacology (IB), Departments of Medicine (SR, QZ,  
RJG, IB, IF), Cancer Biology (BHS, AW) and Pharmacology (RJG,  
IB, IF), Vanderbilt University Medical School, Nashville, TN, USA

I. Feoktistov (✉)  
Vanderbilt University, 360 PRB, 2220 Pierce Ave, Nashville,  
TN 37232-6300, USA  
e-mail: igor.feoktistov@vanderbilt.edu

signaling, linked to upregulation of paracrine factors in cardiac  $\text{Sca1}^+\text{CD31}^-$  cells, is essential for the improvement of cardiac recovery resulting from transplantation of these cells to the injured heart [11]. On the other hand, we found no evidence that  $\text{A}_{2\text{B}}$  receptors promote cardiomyogenic differentiation of cardiac mesenchymal stem-like cells [10].

Recent evidence suggests that cardiac mesenchymal stem-like cells respond to stimulation with  $\text{TGF}\beta$  in vitro, or to myocardial injury in vivo, by displaying myofibroblast characteristics that include an increased synthesis of extracellular matrix (ECM) components and the expression of the contractile protein  $\alpha$ -smooth muscle actin ( $\alpha\text{SMA}$ ) [23–25]. The rapid accumulation and activity of cardiac myofibroblasts early after myocardial injury is thought to be critical for proper scar formation [26]. Because the  $\text{A}_{2\text{B}}$  adenosine receptor signaling is important for overall improvement of cardiac recovery seen after transplantation of cardiac  $\text{Sca1}^+\text{CD31}^-$  cells to the infarcted heart [11], we hypothesized that it may also play a role in this novel aspect of mesenchymal stem-like cell function. In this study, we examined  $\text{TGF}\beta$ -induced collagen I generation and the expression of  $\alpha\text{SMA}$  by cardiac  $\text{Sca1}^+\text{CD31}^-$  cells in vitro and evaluated the effect of stimulation of  $\text{A}_{2\text{B}}$  adenosine receptors on these events. We also examined temporal changes in  $\alpha\text{SMA}$  and collagen I expression in resident cardiac  $\text{Sca1}^+\text{CD31}^-$  cells in vivo after performing experimental MI in  $\text{A}_{2\text{B}}$  receptor knockout (KO) and wild-type (WT) mice.

## Materials and methods

**Reagents** Dulbecco's Modified Eagle Medium (DMEM) (high glucose) was purchased from Invitrogen Corporation (Carlsbad, CA). Porcine transforming growth factor  $\beta 1$  ( $\text{TGF}\beta 1$ ) and mouse interferon  $\gamma$  ( $\text{IFN}\gamma$ ) were purchased from R&D Systems (Minneapolis, MN). 5'-*N*-ethylcarboxamidoadenosine (NECA), fetal bovine serum (FBS), Antibiotic-Antimycotic solution, and dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis, MO). When used as a solvent, final DMSO concentrations in all assays did not exceed 0.1 %, and the same DMSO concentrations were used in vehicle controls.

**Animals** All studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health. Animal studies were reviewed and approved by the institutional animal care and use committee of Vanderbilt University.  $\text{A}_{2\text{B}}$ KO mice were obtained from Deltagen (San Mateo, CA), and WT C57BL/6 mice were purchased from Harlan World Headquarters (Indianapolis, IN). All of the  $\text{A}_{2\text{B}}$ KO mice used in these studies were backcrossed to the C57BL/6 genetic background for more than 10 generations.

**Myocardial infarction** Surgical procedures to produce myocardial infarction in mice by permanent ligation of the left coronary artery were performed in the Cardiovascular Pathophysiology and Complications Core of the Vanderbilt University Mouse Metabolic Phenotyping Center as previously described [11].

**Mouse cardiac  $\text{Sca1}^+\text{CD31}^-$  stromal cells** Conditionally immortalized cardiac  $\text{Sca1}^+\text{CD31}^-$  stromal cell line was generated as described previously [10] from H-2K<sup>b</sup>-tsA58 transgenic mice carrying a thermolabile T antigen. Cells were propagated on 0.1 % gelatin-coated tissue culture dishes in DMEM (high glucose) medium supplemented with 10 % FBS, 1X Antibiotic-Antimycotic solution, 2 mM glutamine, and 10 ng/ml of  $\text{IFN}\gamma$  under humidified atmosphere of air/ $\text{CO}_2$  (19:1) at a low temperature (33 °C). Six days before experiments, cells were replated and cultured in the absence of  $\text{IFN}\gamma$  at a higher temperature (37 °C) to allow them to revert to their primary phenotype as described previously [10].

**Western blot analysis of collagen type I** To investigate the effect of  $\text{TGF}\beta$  and NECA on the expression, secretion, and deposition of collagen I,  $\text{Sca1}^+\text{CD31}^-$  cells were seeded on tissue culture-treated plates and cultured in DMEM medium supplemented with 10 % FBS, 1X Antibiotic-Antimycotic solution, and 2 mM glutamine for 24 h. Next day, culture media were changed with serum-free media supplemented with 1 ng/ml  $\text{TGF}\beta 1$  and/or 30  $\mu\text{M}$  NECA. After 48 h, conditioned media were collected, and total cell lysates were prepared using SDS lysis buffer. To prepare cell-free ECM, cells were lysed using 25 mM Tris-HCl (pH7.4)/150 mM NaCl/0.5 % Triton X-100/20 mM  $\text{NH}_4\text{OH}$ . Cell debris was washed using deionized water followed by PBS. Cell-free ECM remaining on tissue culture plates was collected using SDS sample buffer with  $\beta$ -mercaptoethanol. Equal volume of conditioned media and cell-free ECM and equal amount of total cell lysates from each treatment were resolved on 8 % SDS-PAGE. After blotting, the membrane was probed with antibodies raised against collagen type I (600-401-103; Rockland, Inc., Rockland, PA) or  $\beta$ -actin (Sigma) as a primary antibody and Streptavidin Poly-HRP Conjugate (Thermo Scientific, Inc., Waltham, MA) and HRP-conjugated anti-rabbit IgG (Santa Cruz Biotechnology, Inc., Dallas, TX) as a secondary antibody. Blots were then developed using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) and quantified by densitometry using ImageJ 1.45s software (National Institutes of Health, Bethesda, MD).

**Flow cytometry** All cells were analyzed either freshly isolated or after treatment with Accutase-Enzyme Cell Detachment Medium (eBioscience, San Diego, CA). Isolation of cardiac stromal cell populations was performed as previously

described [11]. In brief, both right and left ventricles were dissected from hearts, minced, and incubated with 10 ml of Digestion Solution (10 mg/ml collagenase II, 2.5 U/ml dispase II, 1 µg/ml DNase I, and 2.5 mM CaCl<sub>2</sub>) for 20 min at 37 °C. Filtered myocyte-free single-cell suspensions (~5×10<sup>5</sup>) were washed and resuspended in 100 µl of PBS containing 0.5 % BSA and 2 mM EDTA (PBS/BSA/EDTA) and 2 µl of murine Fc block reagent (clone 2.4G, BD Biosciences, San Jose, CA). The cells were then incubated with relevant antibodies for 20 min at 4 °C, washed once with 10 volumes of cold PBS/BSA/EDTA, and resuspended in a final volume of 500 µl. Cell-surface antigens were stained with PE-conjugated anti-mouse CD31 or Sca-1 (eBioscience), PeCy7-conjugated Sca-1 or CD45, anti-CD105-APC or CD31-APC (Biolegend, San Diego, CA), and anti-CD45-V450 (BD Biosciences) antibodies. After treatment with Cytotfix/Cytoperm kit (BD Biosciences), the permeabilized cells were stained for αSMA and collagen type I using monoclonal FITC-conjugated anti-αSMA (Sigma) and biotin-conjugated anti-collagen type I (600-401-103; Rockland, Inc., Rockland, PA) antibodies. Streptavidin-PeCy7 (eBioscience) or Streptavidin-Pacific Blue (Life Technologies) conjugates were used to detect biotin-conjugated antibodies. Mouse IgG2a-FITC (Sigma) and biotin-conjugated rabbit whole IgG (Jackson ImmunoResearch, Inc., West Grove, PA) were used as an isotype control. Viable and non-viable cells were distinguished using LIVE/DEAD<sup>®</sup> Fixable Blue Stain kit (Life Technologies, Carlsbad, CA). Data acquisition was performed using LSRII flow cytometer (BD, Franklin Lakes, NJ), and the data were analyzed with WinList 5.0 software. Antigen negativity was defined as having the same fluorescent intensity as the isotype control.


**Statistical analysis** Data were analyzed using the GraphPad Prism 4.0 software (GraphPad Software Inc., San Diego, CA) and presented as mean±SEM. Comparisons between several treatment groups were performed using one-way ANOVA followed by Bonferroni post-hoc tests. Comparisons between two groups were performed using two-tailed unpaired *t* tests. A *p* value <0.05 was considered significant.

## Results

**Analysis of collagen I generation and the expression of αSMA by cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells in vitro** We have previously shown that mouse cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells, used in the current study, express predominantly the A<sub>2B</sub> subtype of adenosine receptors. Although low levels of A<sub>2A</sub> receptor transcripts were also detected, no evidence of their functional activity was found; only the non-selective adenosine agonist NECA, but not the selective agonist CGS 21680 stimulated


cAMP accumulation in these cells [10]. To determine whether adenosine signaling in cardiac mesenchymal stem-like cells plays a role in the production of the common ECM component collagen I, we cultured mouse cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells on uncoated plastic plates in the absence or presence of the stable adenosine analog NECA (30 µM) and in the absence or presence of the pro-fibrotic factor TGFβ1 (1 ng/ml) for 48 h. Figure 1a shows representative Western blots of conditioned media, cell-free ECM, and cell lysates analyzed with an antibody, which specifically recognizes the pro-α1 chain, the mature α1 chain, and the heterotrimer of type I collagen [27]. The expression of the 140 kDa pro-collagen α1(I) chains was clearly seen in cell lysates, whereas secretion of collagen I into media and its deposition on the plate surface were also evident by immunostaining of higher molecular weight bands representing heteromeric mature forms of type I collagen. Additional lower molecular weight bands seen only in conditioned media but not in extracellular matrix or cell lysates may represent accumulation of products of collagen I degradation. Stimulation of Sca1<sup>+</sup>CD31<sup>-</sup> cells with TGFβ1 resulted in a several-fold increase in intracellular pro-collagen levels, accumulation of extracellular collagen I in conditioned media, and its deposition on the plate surface. Stimulation of adenosine receptors on Sca1<sup>+</sup>CD31<sup>-</sup> cells with NECA, however, had much smaller effects on collagen I levels compared to the effects of TGFβ1. In the absence of TGFβ1, NECA had a tendency to increase intracellular pro-collagen levels and collagen I secretion by 1.4–1.6 fold, though these changes did not reach statistical significance (Fig. 1b). In contrast, stimulation of adenosine receptors in Sca1<sup>+</sup>CD31<sup>-</sup> cells attenuated TGFβ-induced increase in collagen I levels in both conditioned media and ECM deposits by approximately 25 %, though only the changes in collagen I levels in conditioned media reached statistical significance. No difference in intracellular pro-collagen I levels was seen between cells stimulated with TGFβ1 in the absence and presence of NECA (Fig. 1a, b). These results suggest that stimulation of adenosine receptors with NECA in TGFβ-activated Sca1<sup>+</sup>CD31<sup>-</sup> cells primarily inhibits collagen I release into conditioned medium. Conversely, in the absence of TGFβ1, NECA had a tendency to increase both intracellular pro-collagen I levels and collagen I release from non-activated Sca1<sup>+</sup>CD31<sup>-</sup> cells in vitro. The effects of NECA on collagen I secretion were A<sub>2B</sub> receptor-specific because they were not observed in A<sub>2B</sub>KO cells used as an off-target control (Fig. 1c, d).

In a separate set of experiments, we cultured mouse cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells in the absence or presence of 30 µM NECA and in the absence or presence of 1 ng/ml TGFβ1 for 24 h and analyzed the expression of αSMA by fluorescence-activated cytometry sorting (FACS). Representative cytofluorographic dot plots of negative αSMA staining with an isotype-matched non-specific antibody are presented in Online Resource Fig. 1. In our cell culture conditions, even in the absence of TGFβ1



**Fig. 1** Stimulation of adenosine signaling with NECA attenuates TGFβ-induced secretion of collagen type I from cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells in vitro. Representative Western blots (a) and densitometric analysis (b) of collagen type I (α1 chain) in conditioned media, cell-free extracellular matrix (ECM), and total cell lysates obtained after incubation of cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells in the absence (C, N) or presence (T, TN) of 1 ng/ml TGFβ1 and in the absence (C, T) or presence (N, TN) of 10 μM NECA for 48 h. Molecular weight markers are shown on the far right, and β-actin was used as a loading control for analysis of cell lysates. Values are presented as means±SEM of three experiments. Asterisks indicate statistical difference (\*\*\*) compared to values obtained in the absence of TGFβ1, dagger indicates statistical difference (†p<0.05), and ns indicates non-significant differences compared to corresponding values obtained in the absence of NECA by one-way ANOVA with Bonferroni post-hoc tests. Western blots (c) and densitometric analysis (d) of collagen type I (Coll I) secretion into conditioned media from A<sub>2B</sub> knockout (A<sub>2B</sub>KO) Sca1<sup>+</sup>CD31<sup>-</sup> cells are shown as a negative control for A<sub>2B</sub> receptor signaling

and NECA, 14.5±1 % of total cell population expressed αSMA (Fig. 2). Stimulation of cells with TGFβ1 produced a three-fold increase in the proportion of αSMA-positive cells (Fig. 2b) and mean fluorescence intensity of αSMA staining




**Fig. 2** Stimulation of adenosine signaling with NECA has no effect on TGFβ-induced expression of αSMA in cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells in vitro. Representative cytofluorographic dot plots (a) of intracellular αSMA staining in cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells cultured in the absence (control) or presence (TGFβ) of 1 ng/ml TGFβ1 and in the absence (-NECA) or presence (+NECA) of 10 μM NECA for 24 h. The percentages of αSMA-positive cells (b) and their mean fluorescence intensity (ΔMFI) (c) are presented as means±SEM of three experiments. Asterisks indicate statistical differences (\*\*p<0.01, \*\*\*p<0.001) and ns indicates non-significant differences analyzed by one-way ANOVA with Bonferroni post-hoc tests

(Fig. 2c). In contrast, stimulation of adenosine receptors with NECA had no significant effect on the expression of αSMA both in the presence or absence of TGFβ1.


*Analysis of the expression of αSMA and collagen I by cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells in a mouse model of MI* TGFβ1 is only one of a multitude of factors that can promote stromal cell differentiation toward myofibroblast phenotype after myocardial injury. Obviously, stimulation of Sca1<sup>+</sup>CD31<sup>-</sup> cells with

TGF $\beta$ 1 *in vitro* cannot reproduce the complexity of their activation induced by MI in the heart. To gain insight into MI-induced dynamics of  $\alpha$ SMA expression in a general stromal cell population and the potential role of A<sub>2B</sub> receptor signaling, we created experimental MI in A<sub>2B</sub>KO and WT mice by permanent ligation of the left coronary artery. Cardiomyocyte-free cell suspensions were prepared from ventricles collected at different time points after MI induction. Gating strategy for the FACS analysis of  $\alpha$ SMA expression in cardiac non-hematopoietic cells is presented in Online Resource Fig. 2. We found that only a small proportion of cells, representing approximately 2 % of non-hematopoietic cell population, expressed  $\alpha$ SMA in non-infarcted hearts (d0, Fig. 3a). It is likely that this minor cell fraction consisted largely of vascular smooth muscle cells which express  $\alpha$ SMA under normal conditions. MI induced a rapid rise in the proportion of  $\alpha$ SMA-expressing cells in the population of stromal (CD31<sup>-</sup>) but not endothelial (CD31<sup>+</sup>) cells (Fig. 3a). An increase in numbers of  $\alpha$ SMA-positive stromal cells, which peaked by post-MI day 5, was followed by gradual decline in their numbers over the next 16 days to nearly pre-infarct levels (Fig. 3b). Whereas no difference in numbers of  $\alpha$ SMA-expressing cells was seen between A<sub>2B</sub>KO and WT hearts during their rise on post-MI days 3 and 5, the numbers of  $\alpha$ SMA-expressing cells remained significantly higher in WT compared with A<sub>2B</sub>KO hearts during their decline (Fig. 3b). To determine if an increase in  $\alpha$ SMA-expressing cell death rate in A<sub>2B</sub>KO hearts could contribute to this phenomenon, we analyzed changes in cell viability produced by MI on days 3, 7, and 14 in myocyte-free cell suspensions obtained from A<sub>2B</sub>KO and WT ventricles. As seen in Fig. 4a, MI produced an initial rise in proportion of non-viable cells by 13 % on day 3, which was reversed by days 7 and 14 comprising only 1.7–2.8 % of total cell populations. However, we found no significant differences between WT and A<sub>2B</sub>KO hearts in MI-induced total cell death (Fig. 4a) or proportion of  $\alpha$ SMA-expressing stromal cells within non-viable cell populations (Fig. 4b). Proportion of non-viable  $\alpha$ SMA-expressing stromal cells in A<sub>2B</sub>KO hearts tended to be even lower compared to WT hearts on post-MI days 7 and 14 suggesting that accelerated decline in  $\alpha$ SMA-expressing stromal cell populations in A<sub>2B</sub>KO versus WT hearts seen in Fig. 3 cannot be explained by their higher death rate.

Next, we selected post-MI days 7 and 14 to determine if there was also a difference in numbers of Sca1<sup>+</sup>CD31<sup>-</sup> cells between A<sub>2B</sub>KO and WT hearts. Representative cytofluorographic dot plots of negative Sca1<sup>+</sup> staining with an isotype-matched non-specific antibody are presented in Online Resource Fig. 3. Normal non-infarcted A<sub>2B</sub>KO and WT hearts contained similar populations of Sca1<sup>+</sup>CD31<sup>-</sup> cells (d0, Fig. 5). In agreement with previous reports [6, 10], MI induced a significant increase in Sca1<sup>+</sup>CD31<sup>-</sup> cell numbers. We found that proportion of Sca1<sup>+</sup>CD31<sup>-</sup>



**Fig. 3** A<sub>2B</sub> receptor signaling controls deactivation of  $\alpha$ SMA expression in total stromal cell population of infarcted ventricles. Representative cytofluorographic outlier contour plots of CD31 and  $\alpha$ SMA expression (a) and the numbers of CD31<sup>-</sup> stromal cells expressing  $\alpha$ SMA per milligram of tissue (b) in CD45<sup>-</sup> myocyte-free cell populations obtained from ventricles of WT and A<sub>2B</sub>KO hearts before (d0) and on different days (d3–d21) after MI. Values are means  $\pm$  SEM of 4–6 animals in each group. Asterisks indicate statistical differences (\* $p$ <0.05, \*\* $p$ <0.01) between WT and A<sub>2B</sub>KO values analyzed at each time point by unpaired two-tailed *t* test



**Fig. 4** Comparative analysis of MI-induced changes in non-viable cell populations from WT and A<sub>2B</sub>KO ventricles. MI-induced changes in total cell viability (a) determined as difference ( $\Delta$ ) between percentages of non-viable cells in total myocyte-free cell populations obtained from ventricles of WT and A<sub>2B</sub>KO mice on days 3, 7, and 14 post-MI and percentages of non-viable cells in total myocyte-free cell populations obtained from non-infarcted ventricles of corresponding control mice. Percentages of  $\alpha$ -SMA-expressing stromal (CD31<sup>-</sup>) cells (b) in non-viable myocyte-free cell populations obtained from ventricles of WT and A<sub>2B</sub>KO mice on days 3, 7, and 14 post-MI. Values are means  $\pm$  SEM of 4–6 animals in each group


cells in non-hematopoietic cell population (Fig 5b) and their numbers (Fig 5c) were significantly higher in WT compared with A<sub>2B</sub>KO hearts on post-MI days 7 and 14. Finally, we analyzed the expression of  $\alpha$ SMA and collagen I in the populations of Sca1<sup>+</sup>CD31<sup>-</sup> cells obtained from A<sub>2B</sub>KO and WT hearts. Representative cytofluorographic dot plots of negative  $\alpha$ SMA and collagen I staining with control isotype-matched antibodies are presented in Online Resource Fig. 4. Before MI, the majority of the cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cell population (over 75 %) were double-negative for  $\alpha$ SMA and collagen I expression; an even greater proportion of Sca1<sup>+</sup>CD31<sup>-</sup> cells (>90 %) were negative for the expression of  $\alpha$ SMA (d0, Fig. 6). MI induced a significant increase in proportion of Sca1<sup>+</sup>CD31<sup>-</sup> cells expressing  $\alpha$ SMA on post-MI days 7 and 14. Remarkably, the MI-induced changes in  $\alpha$ SMA-expressing Sca1<sup>+</sup>CD31<sup>-</sup> cell numbers (Fig. 6b, c) followed dynamics seen in total Sca1<sup>+</sup>CD31<sup>-</sup> cell population

(Fig. 5c), whereas the numbers of  $\alpha$ SMA-negative Sca1<sup>+</sup>CD31<sup>-</sup> cells were not significantly altered by MI (Fig. 6d, e). Thus, our data suggest that the increase in total Sca1<sup>+</sup>CD31<sup>-</sup> cell population induced by MI occurs primarily due to generation of  $\alpha$ SMA-expressing Sca1<sup>+</sup>CD31<sup>-</sup> cells. Although some of the newly generated  $\alpha$ SMA-expressing Sca1<sup>+</sup>CD31<sup>-</sup> cells also expressed collagen I (Fig. 6b), a substantial number of  $\alpha$ SMA-expressing Sca1<sup>+</sup>CD31<sup>-</sup> remained collagen-negative (Fig. 6c). Again, the numbers of  $\alpha$ SMA-expressing Sca1<sup>+</sup>CD31<sup>-</sup> both negative and positive for the expression of collagen I were significantly higher in WT compared with A<sub>2B</sub>KO hearts on post-MI days 7 and 14 (Fig 6b, c), whereas ablation of A<sub>2B</sub> receptor signaling in A<sub>2B</sub>KO hearts had no significant effect on the numbers of  $\alpha$ SMA-negative Sca1<sup>+</sup>CD31<sup>-</sup> cells (Fig 6d, e). Taken together, our results indicate that A<sub>2B</sub> adenosine receptor signaling delays the reversal of Sca1<sup>+</sup>CD31<sup>-</sup> cells from their differentiated myofibroblast-like state back to their resting state.

## Discussion

Cardiac mesenchymal stem-like cells received much attention lately due to their potential to transdifferentiate into various cell lineages. Under appropriate cell culture conditions, these cells can undergo cardiomyogenic, osteogenic, adipogenic, and chondrogenic differentiation [4, 10, 12, 23]. We have previously reported that stimulation of A<sub>2B</sub> receptors on cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells had no effect on their in vitro differentiation toward cardiomyogenic, osteogenic, or adipogenic lineages [10]. In this study, we also found no significant effect of stimulation of A<sub>2B</sub> receptors on the expression of the myofibroblast marker  $\alpha$ SMA in cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cultured in the presence of TGF $\beta$ . The steady-state levels of intracellular pro-collagen I were also unaffected, but TGF $\beta$ -induced secretion of collagen I into media and its deposition on the plate surface were attenuated by stimulation of adenosine receptors. Similar adenosine A<sub>2B</sub> receptor-dependent effects on collagen synthesis in vitro have been reported in serum-activated rat cardiac fibroblasts [28–32] suggesting that adenosine may play an anti-fibrotic role in the heart. In contrast, non-activated cardiac human fibroblasts treated with NECA demonstrated an increase in collagen secretion [33]. Furthermore, rat fibroblasts overexpressing A<sub>2B</sub> adenosine increased collagen synthesis in response to NECA [30]. In the current study, we also observed a tendency of non-activated Sca1<sup>+</sup>CD31<sup>-</sup> cells to increase intracellular pro-collagen I levels and collagen I secretion in response to NECA. These effects were A<sub>2B</sub> receptor-specific because NECA had no effect on A<sub>2B</sub>KO cells. Thus, A<sub>2B</sub> receptor-dependent regulation of collagen I production by cardiac

**Fig. 5** Comparative analysis of MI-induced changes in cardiac Sca1<sup>+</sup>CD31<sup>-</sup> stromal cell populations of WT and A<sub>2B</sub>KO ventricles. Representative cytofluorographic dot plots (a) of CD31 and Sca1 cell-surface staining of CD45<sup>-</sup> myocyte-free cell populations obtained from ventricles of WT and A<sub>2B</sub>KO hearts before (d0) and on days 7 (d7) and 14 (d14) after MI. The percentages (b) and the numbers of Sca1<sup>+</sup>CD31<sup>-</sup> per milligram of tissue (c) are presented as means±SEM of five animals in each group. Asterisks indicate statistical differences (\**p*<0.05, \*\**p*<0.01) between corresponding WT and A<sub>2B</sub>KO values analyzed by one-way ANOVA with Bonferroni post-hoc tests



Sca1<sup>+</sup>CD31<sup>-</sup> stromal cells by adenosine in vitro is similar to that previously found in cardiac fibroblasts, which is highly dependent on culture conditions and particularly on their activation status. Importantly, treatment of Sca1<sup>+</sup>CD31<sup>-</sup> stromal cells with NECA had no effect on the expression of  $\alpha$ SMA in these cells regardless of their activation status.


In vivo, analysis of MI-induced  $\alpha$ SMA expression in cardiac stromal cell population revealed a complex, dynamic, and time-dependent process. A rapid accumulation of  $\alpha$ SMA-expressing cells was seen, reaching a maximum by post-MI day 5. The rapid accumulation of  $\alpha$ SMA-expressing myofibroblasts in the injured area is believed to be important for scar contraction and proper wound healing [26]. Abrogation of A<sub>2B</sub> receptor signaling in A<sub>2B</sub>KO mice had no effect on the increase of  $\alpha$ SMA-expressing cells. Thus, our in vivo results are in agreement with data obtained in cell culture experiments suggesting that A<sub>2B</sub> receptors play no role in generation of  $\alpha$ SMA-expressing cells.

The deactivation of myofibroblasts is also believed to be critical for proper scar formation [26]. This process may involve apoptotic clearance [34] or de-differentiation of myofibroblasts accompanied by the loss of  $\alpha$ SMA expression [35–37]. Indeed, after reaching their peak, the numbers of

$\alpha$ SMA-expressing cells progressively declined over the next 16 days to nearly pre-infarct levels. It is during this phase when the difference between A<sub>2B</sub>KO and WT hearts becomes evident; the numbers of  $\alpha$ SMA-expressing cells remained significantly higher in WT compared with A<sub>2B</sub>KO hearts. At the same time, we found no significant difference in proportion of non-viable  $\alpha$ SMA-expressing cells between WT and A<sub>2B</sub>KO hearts. Taken together, our data suggest that A<sub>2B</sub> receptor signaling promotes retention of  $\alpha$ SMA-expressing cells more likely by delaying myofibroblast de-differentiation rather than due to a decrease in their death rate. Although the precise mechanism of A<sub>2B</sub> receptor-dependent regulation of the deactivation of  $\alpha$ SMA-expressing cells remains to be addressed in future cell-fate tracking experiments, our current study revealed a new level of complexity of adenosine actions in the heart. It also demonstrated that the effects of A<sub>2B</sub> receptors in the regulation of scar formation are time-dependent, and its role in this process may become more important at the healing phase of myocardial infarction.

The ramifications of altering the temporal regulation of  $\alpha$ SMA-expressing cells on myocardial scar properties require further investigation. In support of beneficial effects of A<sub>2B</sub> receptor signaling in myocardial repair, it has been reported

**Fig 6** Comparative analysis of MI-induced changes in  $\alpha$ SMA and collagen I expression in cardiac Sca1<sup>+</sup>CD31<sup>-</sup> stromal cell populations of WT and A<sub>2B</sub>KO ventricles. Representative cytofluorographic dot plots (a) of intracellular  $\alpha$ SMA and collagen I (Col1) expression in cardiac Sca1<sup>+</sup>CD31<sup>-</sup> stromal cell populations obtained from ventricles of WT and A<sub>2B</sub>KO hearts before (d0) and on days 7 (d7) and 14 (d14) after MI. The numbers of  $\alpha$ SMA<sup>+</sup>Col1<sup>+</sup> (b),  $\alpha$ SMA<sup>+</sup>Col1<sup>-</sup> (c),  $\alpha$ SMA<sup>-</sup>Col1<sup>-</sup> (d), and Col1<sup>+</sup> $\alpha$ SMA<sup>-</sup> (e) cells per milligram of tissue are presented as means $\pm$ SEM of 4 animals in each group. Asterisks indicate statistical differences (\* $p$ <0.05, \*\* $p$ <0.01) between corresponding WT and A<sub>2B</sub>KO values analyzed by one-way ANOVA with Bonferroni post-hoc tests



that long-term stimulation of A<sub>2B</sub> receptors started one week after MI infarction significantly ameliorated adverse remodeling in the injured heart [38]. In contrast, activation of A<sub>2B</sub> receptor signaling at earlier stages of MI has been suggested to contribute to adverse remodeling by promoting an inflammatory response [39]. The retention of  $\alpha$ SMA-expressing cells may help keep the injured tissue strong and contracted, thus preserving it from potential rupture. On the other hand, abnormal persistence of  $\alpha$ SMA-expressing myofibroblasts may lead to interstitial fibrosis resulting in exaggerated mechanical stiffness, disorganized contraction, and worsening myocardial ischemia. In support of the latter concept, it has been reported that only WT but not A<sub>2B</sub>KO mice developed reactive interstitial fibrosis in response to MI [40]. Furthermore, inhibition of A<sub>2B</sub> receptors with the selective antagonist GS-6201 reduced interstitial fibrosis in response to MI [41]. Although seemingly contradictory, these studies demonstrated a multifaceted and time-dependent regulation of MI-induced remodeling by A<sub>2B</sub> receptors. Due to well-known limitations of studies involving global knockout or systemic pharmacological modulation of A<sub>2B</sub> receptor signaling in such a complex process as MI, it is difficult to differentiate the direct effects of adenosine on stromal cells from indirect effects of other cells, e.g., invading leukocytes also known to be regulated by adenosine via A<sub>2B</sub> adenosine receptors [42, 43].

Despite these limitations, our study demonstrated for the first time that resident cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells represent a substantial population of MI-induced  $\alpha$ SMA-expressing cells and therefore can actively participate in scar formation. Furthermore, a proportion of Sca1<sup>+</sup>CD31<sup>-</sup> in total non-hematopoietic cell population and their numbers increased nearly two-fold one week after MI and remained significantly higher in WT compared with A<sub>2B</sub>KO hearts. Analysis of  $\alpha$ SMA and collagen I expression suggested that almost all MI-induced changes in total Sca1<sup>+</sup>CD31<sup>-</sup> cell population can be attributed to generation of  $\alpha$ SMA-expressing Sca1<sup>+</sup>CD31<sup>-</sup> cells comprised of both collagen-positive and collagen-negative populations. Like in general CD31<sup>-</sup> stromal cell population, the numbers of these cells remained significantly higher in WT compared with A<sub>2B</sub>KO hearts indicating that their deactivation is regulated by the A<sub>2B</sub> receptor signaling. Thus, we conclude that A<sub>2B</sub> receptors play an important role in the regulation of dynamic changes in populations of  $\alpha$ SMA-expressing Sca1<sup>+</sup>CD31<sup>-</sup> stromal cells induced by MI.

In summary, our study revealed a significant contribution of cardiac Sca1<sup>+</sup>CD31<sup>-</sup> cells to the accumulation of  $\alpha$ SMA-expressing cells after MI and implicated A<sub>2B</sub> receptor signaling in regulation of myocardial repair and remodeling by delaying deactivation of these cells. It is plausible that this phenomenon may also contribute in part to the beneficial



effects of mesenchymal stem-like cells seen after their transplantation to the injured heart.

**Acknowledgements** This work was supported by the National Institutes of Health National Heart, Lung and Blood Institute [grant R01HL095787 and K08HL094703], National Cancer Institute [grant R01CA138923], American Heart Association Research Grant-in-Aid [13GRNT16580020], and Vanderbilt Clinical and Translational Science Award (CTSA) [grant UL1 RR024975-01] from the National Institutes of Health National Center for Research Resources (Vanderbilt Institute for Clinical and Translational Research CTSA grant VR5622).

## References

- Rossini A, Frati C, Lagrasta C, Graiani G, Scopece A, Cavalli S, Musso E, Baccarin M, Di SM, Fagnoni F, Germani A, Quaini E, Mayr M, Xu Q, Barbuti A, DiFrancesco D, Pompilio G, Quaini F, Gaetano C, Capogrossi MC (2011) Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin. *Cardiovasc Res* 89:650–660
- Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, Matsushita N, Blusztajn A, Terrovitis J, Kusuoka H, Marban L, Marban E (2012) Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. *J Am Coll Cardiol* 59:942–953
- Huang C, Gu H, Yu Q, Manukyan MC, Poynter JA, Wang M (2011) Sca-1<sup>+</sup> cardiac stem cells mediate acute cardioprotection via paracrine factor SDF-1 following myocardial ischemia/reperfusion. *PLoS One* 6:e29246
- Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, Sano M, Toko H, Akazawa H, Sato T, Nakaya H, Kasanuki H, Komuro I (2004) Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. *J Biol Chem* 279:11384–11391
- Pfister O, Mouquet F, Jain M, Summer R, Helmes M, Fine A, Colucci WS, Liao R (2005) CD31<sup>-</sup> but Not CD31<sup>+</sup> cardiac side population cells exhibit functional cardiomyogenic differentiation. *Circ Res* 97:52–61
- Wang X, Hu Q, Nakamura Y, Lee J, Zhang G, From AH, Zhang J (2006) The role of the sca-1<sup>+</sup>/CD31<sup>-</sup> cardiac progenitor cell population in postinfarction left ventricular remodeling. *Stem Cells* 24:1779–1788
- Mohri T, Fujio Y, Obana M, Iwakura T, Matsuda K, Maeda M, Azuma J (2009) Signals through glycoprotein 130 regulate the endothelial differentiation of cardiac stem cells. *Arterioscler Thromb Vasc Biol* 29:754–760
- Liang SX, Tan TY, Gaudry L, Chong B (2010) Differentiation and migration of Sca1<sup>+</sup>/CD31<sup>-</sup> cardiac side population cells in a murine myocardial ischemic model. *Int J Cardiol* 138:40–49
- Matsuura K, Honda A, Nagai T, Fukushima N, Iwanaga K, Tokunaga M, Shimizu T, Okano T, Kasanuki H, Hagiwara N, Komuro I (2009) Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. *J Clin Invest* 119:2204–2217
- Ryzhov S, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I, Feoktistov I (2012) Role of A<sub>2B</sub> adenosine receptors in regulation of paracrine functions of stem cell antigen 1-positive cardiac stromal cells. *J Pharmacol Exp Ther* 341:764–774
- Ryzhov S, Zhang Q, Biaggioni I, Feoktistov I (2013) Adenosine A<sub>2B</sub> receptors on cardiac stem cell antigen (Sca)-1-positive stromal cells play a protective role in myocardial infarction. *Am J Pathol* 183:665–672
- Tateishi K, Ashihara E, Takehara N, Nomura T, Honsho S, Nakagami T, Morikawa S, Takahashi T, Ueyama T, Matsubara H, Oh H (2007) Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration. *J Cell Sci* 120:1791–1800
- Takamiya M, Haider KH, Ashraf M (2011) Identification and characterization of a novel multipotent sub-population of Sca-1<sup>+</sup> cardiac progenitor cells for myocardial regeneration. *PLoS One* 6:e25265
- Martin BJ, McClanahan TB, Van Wylen DG, Gallagher KP (1997) Effects of ischemia, preconditioning, and adenosine deaminase inhibition on interstitial adenosine levels and infarct size. *Basic Res Cardiol* 92:240–251
- Willems L, Reichelt ME, Molina JG, Sun CX, Chunn JL, Ashton KJ, Schnermann J, Blackburn MR, Headrick JP (2006) Effects of adenosine deaminase and A<sub>1</sub> receptor deficiency in normoxic and ischemic mouse hearts. *Cardiovasc Res* 71:79–87
- Fredholm BB (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. *Cell Death Differ* 14:1315–1323
- Gharibi B, Abraham AA, Ham J, Evans BA (2012) Contrasting effects of A<sub>1</sub> and A<sub>2B</sub> adenosine receptors on adipogenesis. *Int J Obes (Lond)* 36:397–406
- Gharibi B, Abraham AA, Ham J, Evans BA (2011) Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes. *J Bone Miner Res* 26:2112–2124
- Ham J, Evans BA (2012) An emerging role for adenosine and its receptors in bone homeostasis. *Front Endocrinol (Lausanne)* 3:113
- Carroll SH, Wigner NA, Kulkarni N, Johnston-Cox H, Gerstenfeld LC, Ravid K (2012) A<sub>2B</sub> adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. *J Biol Chem* 287:15718–15727
- Ciciarello M, Zini R, Rossi L, Salvestrini V, Ferrari D, Manfredini R, Lemoli RM (2013) Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages. *Stem Cells Dev* 22:1097–1111
- He W, Mazumder A, Wilder T, Cronstein BN (2013) Adenosine regulates bone metabolism via A<sub>1</sub>, A<sub>2A</sub>, and A<sub>2B</sub> receptors in bone marrow cells from normal humans and patients with multiple myeloma. *FASEB J* 27:3446–3454
- Carlson S, Trial J, Soeller C, Entman ML (2011) Cardiac mesenchymal stem cells contribute to scar formation after myocardial infarction. *Cardiovasc Res* 91:99–107
- Cieslik KA, Trial J, Entman ML (2011) Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart rescue by activation of the AMPK pathway. *Am J Pathol* 179:1792–1806
- Cieslik KA, Trial J, Carlson S, Taffet GE, Entman ML (2013) Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. *FASEB J* 27:1761–1771
- van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J (2010) Myocardial remodeling after infarction: the role of myofibroblasts. *Nat Rev Cardiol* 7:30–37
- Stefanovic B, Schnabl B, Brenner DA (2002) Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. *J Biol Chem* 277:18229–18237
- Dubey RK, Gillespie DG, Mi Z, Jackson EK (1997) Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A<sub>2B</sub> receptors. *Circulation* 96:2656–2666
- Dubey RK, Gillespie DG, Jackson EK (1998) Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A<sub>2B</sub> receptors. *Hypertension* 31:943–948
- Chen Y, Epperson S, Makhstudova L, Ito B, Suarez J, Dillmann W, Villarreal F (2004) Functional effects of enhancing or silencing adenosine A<sub>2B</sub> receptors in cardiac fibroblasts. *Am J Physiol* 287:H2478–H2486

31. Epperson SA, Brunton LL, Ramirez-Sanchez I, Villarreal F (2009) Adenosine receptors and second messenger signaling pathways in rat cardiac fibroblasts. *Am J Physiol Cell Physiol* 296:C1171–C1177
32. Villarreal F, Epperson SA, Ramirez-Sanchez I, Yamazaki KG, Brunton LL (2009) Regulation of cardiac fibroblast collagen synthesis by adenosine: roles for Epac and PI3K. *Am J Physiol* 296:C1178–C1184
33. Zhong H, Belardinelli L, Zeng D (2011) Pro-fibrotic role of the A<sub>2B</sub> adenosine receptor in human cardiac fibroblasts. *J Card Fail* 17:S65
34. Desmouliere A, Redard M, Darby I, Gabbiani G (1995) Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. *Am J Pathol* 146:56–66
35. Hecker L, Jagirdar R, Jin T, Thannickal VJ (2011) Reversible differentiation of myofibroblasts by MyoD. *Exp Cell Res* 317:1914–1921
36. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA (2012) Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. *Proc Natl Acad Sci U S A* 109:9448–9453
37. Garrison G, Huang SK, Okunishi K, Scott JP, Kumar Penke LR, Scruggs AM, Peters-Golden M (2013) Reversal of myofibroblast differentiation by prostaglandin E<sub>2</sub>. *Am J Respir Cell Mol Biol* 48: 550–558
38. Wakeno M, Minamino T, Seguchi O, Okazaki H, Tsukamoto O, Okada K, Hirata A, Fujita M, Asanuma H, Kim J, Komamura K, Takashima S, Mochizuki N, Kitakaze M (2006) Long-term stimulation of adenosine A<sub>2B</sub> receptors begun after myocardial infarction prevents cardiac remodeling in rats. *Circulation* 114:1923–1932
39. Toldo S, Zhong H, Mezzaroma E, Van TB, Kannan H, Zeng D, Belardinelli L, Voelkel N, Abbate A (2012) GS-6201, a selective blocker of the A<sub>2B</sub> adenosine receptor, attenuates cardiac remodeling following acute myocardial infarction in the mouse. *J Pharmacol Exp Ther* 343:587–595
40. Maas JE, Koupenova M, Ravid K, Auchampach JA (2008) The A<sub>2B</sub> adenosine receptor contributes to post-infarction heart failure. *Circulation* 118:S946
41. Zhang H, Zhong H, Everett TH, Wilson E, Chang R, Zeng D, Belardinelli L, Olgin JE (2014) Blockade of A<sub>2B</sub> adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. *Heart Rhythm* 11:101–109
42. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I, Dikov MM (2008) Adenosine receptors in regulation of dendritic cell differentiation and function. *Blood* 112: 1822–1831
43. Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I, Feoktistov I (2008) Effect of A<sub>2B</sub> adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. *J Pharmacol Exp Ther* 324:694–700